3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neoplasms
5
Multiple Myeloma
3
Hematologic Neoplasms
3
Thyroid Cancer, Papillary
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Carcinoma, Anaplastic
1
Rare Tumor
1
Ovarian Neoplasms
1
Lymphoproliferative Disorders
1
Leukemia, Hairy Cell
1
Laryngeal Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Cancer Metastatic
1
Adenocarcinoma, Follicular
1
Interventions
atezolizumab
3
fludarabine
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Pemetrexed
2
Nivolumab
2
Cisplatin
2
spartalizumab
1
repotrectinib
1
pertuzumab
1
lutetium Lu 177 dotatate
1
gilteritinib
1
enzalutamide
1
durvalumab
1
copper dotatate CU-64
1
cemiplimab
1
Trastuzumab
1
Sodium Chloride
1
Radiotherapy
1
Radiosurgery
1
Mitomycin
1
Lutetium-177
1
Lutetium
1
Injections
1
Idarubicin
1
HuMax-IL8
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms by Histologic Type
×
Vemurafenib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled